Altus Wealth Group’s BioNTech BNTX Stock Holding History

Altus Wealth Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250	Closed	-$20K	–	239
2020 Q4	$20K	Buy	+250	New	+$24.5K	0.02%	364

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Altus Wealth Group's BNTX Position: Q1 2021 in Review

Altus Wealth Group sold out of BioNTech (BNTX) in Q1 2021, closing a stake of 250 shares — an estimated $20K sold.

Altus Wealth Group first reported a position in BNTX in Q4 2020 and held it in 1 quarter. The position peaked at $20K in Q4 2020. 225 funds tracked by Wall St. Rank hold BNTX as of Q1 2021.

Altus Wealth Group reported no remaining BioNTech position as of Q1 2021 after selling out during the quarter.
Altus Wealth Group sold 250 BioNTech shares in Q1 2021, an estimated $20K.
Altus Wealth Group first reported a position in BioNTech in Q4 2020 and held it in 1 quarter.
Altus Wealth Group's BioNTech position peaked at $20K in Q4 2020.
225 funds tracked by Wall St. Rank held BioNTech as of Q1 2021.

Based on Altus Wealth Group's 13F filing for Q1 2021, filed 14 May 2021.